Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-22 19:12 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Phase not reported / not applicableCompletedOBSERVATIONAL
Start: 2013-10-18. Completion: 2019-11-29 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 47 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Research Site Aichi, Japan Site recruitment: Not reported
Research Site Akita, Japan Site recruitment: Not reported
Aomori, Japan
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Start: 2007-10. Completion: 2008-09 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Garvan Institute of Medical Research Sydney, New South Wales, Australia Site recruitment: Not reported
Start: 2020-01-05. Completion: 2020-01-31 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide treatment (drug) — also listed as: exenatide
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Beijing Chao-yang hospital Beijing, China Site recruitment: Not reported
Start: 2020-06-30. Completion: 2021-07-02 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide Once-Weekly Suspension (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Start: 2012-09. Completion: 2017-10 (may be estimated). Results are posted in this registry.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Royal Surrey County Hospital Guildford, United Kingdom Site recruitment: Not reported
Imperial Weight Centre London, United Kingdom Site recruitment: Not reported
Start: 2018-02-19. Completion: 2019-08-05 (may be estimated). No results posted in this registry response.
Products and interventions (6)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Dapagliflozin 10mg (drug)
Exenatide 2 mg [Bydureon] (drug)
Placebo Oral Tablet (drug)
Placebo injection (drug)
Insulin (drug)
Metformin, if taken before (drug)
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Diabeteszentrum Oldenburg Oldenburg, Lower Saxony, Germany Site recruitment: Not reported
University Medical Center Hamburg-Eppendorf Hamburg, Germany Site recruitment: Not reported
Diabetologische Schwerpunktpraxis Harburg Hamburg, Germany Site recruitment: Not reported
Gemeinschaftspraxis für Innere Medizin und Diabetologie Hamburg, Germany Site recruitment: Not reported
Start: 2017-11-17. Completion: 2021-11-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide LAR (drug) — also listed as: Bydureon
Dulaglutide (drug) — also listed as: Trulicity
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Instituto de terapeutica Experimental y Clinica. Centro universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico Site recruitment: Recruiting
Start: 2013-09. Completion: 2019-08 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (Bydureon®) (drug)
Placebo (drug)
Where the study takes place — 8 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University of California, San Francisco San Francisco, California, United States Site recruitment: Not reported
Barbara Davis Center Aurora, Colorado, United States Site recruitment: Not reported
Yale University New Haven, Connecticut, United States Site recruitment: Not reported
University of Miami Miami, Florida, United States Site recruitment: Not reported
University of Chicago Chicago, Illinois, United States Site recruitment: Not reported
Joslin Diabetes Center Boston, Massachusetts, United States Site recruitment: Not reported
University of Michigan Ann Arbor, Michigan, United States Site recruitment: Not reported
SUNY Upstate Medical University Syracuse, New York, United States Site recruitment: Not reported
Start: 2014-03-01. Completion: 2020-02-29 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
SGLT2 inhibitor (drug)
GLP-1 receptor agonist (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Division of Metabolic Diseases, University Hospital of Padova Padova, Italy Site recruitment: Not reported
Start: 2016-04-08. Completion: 2019-12-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug) — also listed as: Byetta
Lispro (drug) — also listed as: Humalog
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Start: 2015-08. Completion: 2020-08 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug) — also listed as: Byetta
Desacyl ghrelin (biological) — also listed as: Unacylated ghrelin
Saline (biological)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, Hammersmith Hospital London, United Kingdom Site recruitment: Not reported
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Countries with listed sites
Russia
Registry dates and results
Start: 2017-08-01. Completion: 2020-05 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Automatic system guided treatment (drug)
Standard treatment (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Alina Babenko Saint Petersburg, Russia Site recruitment: Recruiting
Nanjing First Hospital, Nanjing Medical University
Countries with listed sites
China
Registry dates and results
Start: 2019-05-05. Completion: 2020-05-05 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
68Ga-NOTA-MAL-Cys39-exendin-4 (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Nanjing First Hospital Nanjing, Jiangsu, China Site recruitment: Recruiting
Austria · Germany · Puerto Rico · United Kingdom · United States
Registry dates and results
Start: 2014-02. Completion: 2015-10 (may be estimated). Results are posted in this registry.
Products and interventions (10)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Glimepiride (drug)
Metformin (drug)
Pioglitazone (drug)
Acarbose (drug)
Linagliptin (drug)
Sitagliptin (drug)
Liraglutide (drug)
Insulin Glargine (drug)
Exenatide once weekly (QW) (drug)
Exenatide twice daily (BID) (drug)
Where the study takes place — 34 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Suncoast Research Group, LLC Miami, Florida, United States Site recruitment: Not reported
New Horizon Research Center Miami, Florida, United States Site recruitment: Not reported
Suncoast Clinical Research New Port Richey, Florida, United States Site recruitment: Not reported
Florida Hospital Orlando, Florida, United States Site recruitment: Not reported
Athens Primary Care Athens, Georgia, United States Site recruitment: Not reported
Herman Clinical Research, LLC Suwanee, Georgia, United States Site recruitment: Not reported
Rocky Mountain Diabetes and Osteoporosis Center Idaho Falls, Idaho, United States Site recruitment: Not reported
Iderc, P.L.C. Des Moines, Iowa, United States Site recruitment: Not reported
Cotton O'Neil Clinic Topeka, Kansas, United States Site recruitment: Not reported
Mercy Health Research St Louis, Missouri, United States Site recruitment: Not reported
Southern New Hampshire Diabetes and Endocrinology Nashua, New Hampshire, United States Site recruitment: Not reported
Heritage Valley Medical Group, Inc. Beaver, Pennsylvania, United States Site recruitment: Not reported
Family Medical Associates Levittown, Pennsylvania, United States Site recruitment: Not reported
Carolina Health Specialists Myrtle Beach, South Carolina, United States Site recruitment: Not reported
Dallas Diabetes Endocrine Center Dallas, Texas, United States Site recruitment: Not reported
Rockwood Clinic Research Center Spokane, Washington, United States Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Saint Stefan Ob Stainz, Austria Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Salzburg, Austria Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vienna, Austria Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vienna, Austria Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Berlin, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dortmund, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hamburg, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Mainz, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Münster, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Neuwied, Germany Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Stuttgart, Germany Site recruitment: Not reported
Manati Medical Center Manati, Puerto Rico Site recruitment: Not reported
American Telemedicine Center San Juan, Puerto Rico Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Salford, Manchester, United Kingdom Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dundee, Scotland, United Kingdom Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sheffield, South Yorkshire, United Kingdom Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ipswich, Suffolk, United Kingdom Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Manchester, United Kingdom Site recruitment: Not reported
Start: 2010-01. Completion: 2019-03-15 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug) — also listed as: Byetta
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Children's Hospital of Orange County Orange, California, United States Site recruitment: Not reported
Children's Hospitals & Clincis of Minnesota Saint Paul, Minnesota, United States Site recruitment: Not reported
Start: 2013-12. Completion: 2015-02 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
LY3053102 (drug)
Exenatide ER (drug)
Placebo (drug)
Metformin (drug)
Where the study takes place — 5 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Orange County Research Center Orange, California, United States Site recruitment: Not reported
Miami Research Associates Miami, Florida, United States Site recruitment: Not reported
Compass Research Orlando, Florida, United States Site recruitment: Not reported
Clinilabs, Inc (New York) New York, New York, United States Site recruitment: Not reported
Dallas Diabetes Endocrine Center Dallas, Texas, United States Site recruitment: Not reported
Start: 2018-09-19. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
NLY01 (drug) — also listed as: Placebo, normal saline
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
ICON Early Phase Services/CRU San Antonio, Texas, United States Site recruitment: Not reported
Polycystic Ovary Syndrome; Overweight and Obesity; Disorder of Glucose Regulation
Sponsor
RenJi Hospital
Countries with listed sites
China
Registry dates and results
Start: 2017-11-28. Completion: 2018-07-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug) — also listed as: Byetta
Metformin (drug) — also listed as: Glucophage
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Renji Hospital Department of Endocrinology and Metabolism Shanghai, China Site recruitment: Not reported
Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease
Sponsor
Fudan University
Countries with listed sites
China
Registry dates and results
Start: 2015-03. Completion: 2017-11 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Exenatide (drug) — also listed as: Byetta
insulin glargine (drug) — also listed as: Lantus
Where the study takes place — 5 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University Shanghai, Shanghai Municipality, China Site recruitment: Not reported
Department of Endocrinology and Metabolism, Shanghai Minhang Central Hospital Shanghai, Shanghai Municipality, China Site recruitment: Not reported
Department of Endocrinology and Metabolism,Huadong Hospital Shanghai, Shanghai Municipality, China Site recruitment: Not reported
Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital Shanghai, Shanghai Municipality, China Site recruitment: Not reported
Department of Endocrinology and Metabolism,Shanghai Changzheng Hospital Shanghai, Shanghai Municipality, China Site recruitment: Not reported
Start: 2019-07-20. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Metformin (drug) — also listed as: Glucophage
Exenatide 2 MG (drug) — also listed as: Bydureon
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Peking Union Medical College Hospital Beijing, Beijing Municipality, China Site recruitment: Recruiting
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.